Insight Wealth Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.53M Sell
8,617
-117
-1% -$88.4K 0.65% 50
2026
Q2
$5.46M Buy
8,734
+1,850
+27% +$1.26M 0.53% 65
2026
Q1
$5.32M Sell
6,884
-612
-8% -$469K 0.59% 57
2025
Q4
$5.79M Buy
7,496
+218
+3% +$148K 0.66% 40
2025
Q3
$4.09M Buy
+7,278
New +$4.12M 0.48% 69
2021
Q2
– Sell
-429
Closed -$203K – 226
2021
Q1
$203K Sell
429
-6
-1% -$2.92K 0.03% 214
2020
Q4
$210K Buy
435
+77
+22% +$41.6K 0.04% 215
2020
Q3
$200K Buy
358
+34
+10% +$20.6K 0.04% 196
2020
Q2
$202K Buy
+324
New +$184K 0.05% 165

Other funds holding REGN

Insight Wealth Strategies's REGN Position: Q3 2026 in Review

Insight Wealth Strategies reduced its Regeneron Pharmaceuticals (REGN) stake by 1.3% in Q3 2026, selling an estimated $88.4K and leaving 8,617 shares worth $6.53M. The position accounts for 0.65% of the portfolio, ranked #50.

Insight Wealth Strategies first reported a position in REGN in Q2 2020 and has held it in 9 quarters since. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Insight Wealth Strategies held 8,617 shares of Regeneron Pharmaceuticals worth $6.53M as of Q3 2026.
  • Insight Wealth Strategies sold 117 Regeneron Pharmaceuticals shares in Q3 2026, an estimated $88.4K.
  • Regeneron Pharmaceuticals made up 0.65% of Insight Wealth Strategies's portfolio in Q3 2026, its #50 holding.
  • Insight Wealth Strategies first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 9 quarters since.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Insight Wealth Strategies's 13F filing for Q3 2026, filed 9 Oct 2026.